Pnano - a cluster of nanotechnology projects

PNano - Experts in Nanotechnology Pnano is a group of experts developing a cluster of nanotechnology projects. Our team specializes in developing nanotechnology projects ranging from nanooptoelectronics to safe early stage prenatal molecular diagnostics.

Sequenom, Inc developed a sensitive assay for analyzing cell free fetal RNA (cffRNA) and cell free fetal DNA (cffDNA) from the mother's periferal blood to test the fetus for chromosomal abnormalities and genetic defects. According to third-party publications, cffRNA and cffDNA can be detected in mother's blood as early as 5/6th week of pregnancy.
Sequenom's highly accurate, efficient and sensitive method uses nanotechnology to test for chromosomal abnormalities including trisomy of chromosomes 21 (Down's syndrome), 18 (Edward's syndrome), 13 (Patau syndrome) as well as for genetic disorders including RHD, Y-chromosome related disorders, cystic fibrosis and wide spectrum of other diseases.

Recently the company announced that the test will be delayed and will hit the market after large-scale independant trials are concluded. Preliminary time frame is Q4/09-Q1/10. The announcement resulted in a 75% drop in the stock price.

At current prices the company looks like a steal and prenatal diagnostic centers worldwide should consider this technology.

1 comments:

The company delayed the test offering because they said their employees mishandled data and that all previously reported data from the company had to be consider invalid. That is why the stock dropped 75 percent. Right now, with no valid data, I don't know how you can say Sequenom's methods is "highly accurate, efficient and sensitive." I think that is speculation not currently supported by the facts.

Post a Comment